PeptidePedia The community reference

Talk:GLP-1 receptor agonist

Discussion page·4 threads·1 archive

This article is within the scope of the pharmacology working group.
Rated A-class. This is a high-traffic entry point; changes to the lead should be discussed first.

This is the discussion page for the article GLP-1 receptor agonist. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Should class-level cardiovascular benefit be claimed?Resolved

The efficacy section originally said "the class reduces cardiovascular events". Outcome trials were run on individual molecules at individual doses. Reworded to attribute the finding to the trials that produced it. — BalanceBirdie (talk) 11:30, 17 January 2026 (UTC)

Correct call. Lixisenatide's outcome trial was neutral, which by itself defeats a class claim. The current wording is defensible. — SelectTrialSam (talk) 15:02, 17 January 2026 (UTC)

Noting for the archive that this is the third time the class-effect sentence has been reinstated by a drive-by edit. A hidden comment now sits above it. ✓ Done — NeutralNikolai (talk) 10:14, 18 January 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Scope: how much research-chemical material belongs here?

The last section covers material sold outside licensed supply. Is that within scope for a pharmacology article, or should it live entirely at Research use only? — ScopeSeverin (talk) 14:05, 22 March 2026 (UTC)

It belongs here in summary form. A reader arriving at this article from a supplier catalogue needs the distinction made on the page they landed on, not two clicks away. The detail should stay at the dedicated article. — Peptide_Pete (talk) 16:48, 22 March 2026 (UTC)

Reasonable. I would keep it to the three paragraphs it currently runs to and resist expansion. — ScopeSeverin (talk) 09:20, 23 March 2026 (UTC)

Requested move: → Glucagon-like peptide-1 receptor agonistRequested move

Requested move. A move of this page has been proposed below. The question is whether the proposed title is the one a reader would most plausibly search for, per Project:Manual of style.

Propose expanding the abbreviation in the title for consistency with Glucagon-like peptide-1. — MoveRequestMio (talk) 10:00, 8 November 2025 (UTC)

Oppose. The abbreviated form is overwhelmingly the common name in both the clinical and the regulatory literature, and unlike the hormone article there is no competing expansion to disambiguate. — ManualOfStyleMo (talk) 12:35, 8 November 2025 (UTC)

Closing as not moved. No support for the move; redirect from the expanded form already exists. — Ref_Desk_Ron (talk) 09:44, 12 November 2025 (UTC)

This page was last edited on 23 March 2026, by ScopeSeverin. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).